Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A171601||Alliance||A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer||Cancer Prevention and Control CIRB||Available to Open|
|A071701||Alliance||Genomically-Guided Treatment Trial in Brain Metastases||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041703||Alliance||Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|A231601CD||Alliance||Improving Surgical Care and Outcomes In Older Cancer Patients Through Implementation of An Efficient Pre-Surgical Toolkit (OPTI-Surg)||Cancer Prevention and Control CIRB||Available to Open|
|A031704||Alliance||PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091404||Alliance||A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221602||Alliance||Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial||Cancer Prevention and Control CIRB||Available to Open|
|A031501||Alliance||Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041702||Alliance||A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221702||Alliance||ARM: Axillary Reverse Mapping – A Prospective Trial To Study Rates Of Lymphedema And Regional Reccurence After Sentinel Lymph Node Biopsy And Sentinel Lymph Node Biopsy Followed By Axillary Lymph Node Dissection With And Without Axillary Reverse Mapping||Cancer Prevention and Control CIRB||Available to Open|